

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AUSTCO HEALTHCARE LIMITED
ABN: 67 108 208 760

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Clayton Astles
Date of last notice	31 July 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-
Date of change	30 October 2025

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>Direct: 3,030,588 Ordinary Shares</p> <p>677,486 Unlisted Performance Rights expiring 30 September 2026</p> <p>821,739 Unlisted Performance Rights expiring 30 November 2027</p> <p>Indirect: 1,440,643 Ordinary Shares (held via HSBC Custody Nominees (Australia) Limited for the Clayton Astles RRSP account)</p> <p>91,804 Ordinary Shares (held via Clayton Astles ATF the Clayton Astles RRSP account)</p>
Class	Unlisted Performance Rights
Number acquired	632,649 Unlisted Performance Rights
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	<p>Direct: 3,030,588 Ordinary Shares</p> <p>677,486 Unlisted Performance Rights expiring 30 September 2026</p> <p>821,739 Unlisted Performance Rights expiring 30 November 2027</p> <p>632,649 Unlisted Performance Rights expiring 30 November 2028</p> <p>Indirect: 1,440,643 Ordinary Shares (held via HSBC Custody Nominees (Australia) Limited for the Clayton Astles RRSP account)</p> <p>91,804 Ordinary Shares (held via Clayton Astles ATF the Clayton Astles RRSP account)</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of Performance Rights under the ESOP as approved by shareholders at the Annual General Meeting on 29 October 2025.

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.